

Tositumomab I¹³¹ tositumomab

Plan of Care:

Prior to beginning therapy:

1. **Attending must dictate** a note reviewing the patient's history, include all of the following points: (These are medicare requirements, let OPAS review for other carriers)
 - a. Patient has a follicular lymphoma or transformed lymphoma.
 - b. Lymphoma is CD20+
 - c. Patient has been treated with at least 4 doses of rituximab and failed to respond
 - d. No progressive disease in a previously radiated site treated with >3500 cGy within one year of completion of radiation.
 - e. Marrow (done within 1 month of planned treatment) should show <25% involvement with lymphoma
If one marrow shows <10% involvement with lymphoma, no need for second marrow. If first marrow >10% involved, do second marrow and use average of the two percentages
2. Patient should have normal creatinine
3. Patient must have a platelet count $\geq 100,000/\text{mm}^2$
4. Patient must have absolute neutrophil count of $\geq 1,500/\text{mm}^2$
5. Female patients must have a negative pregnancy test, if of childbearing potential.
6. Schedule an appointment for the patient with Dr. Winner (Debbie Pavone X 5341) to discuss administration and precautions
7. Give the patient a prescription for either
 - a. SSKI, 30 ml dropper bottle, take 4 drops po TID (in any liquid) days -1 through +28
or
 - b. KI tablets, 130mg 1 tab po daily, dispense 30 day supply days -1 through +28
8. Notify Nurse coordinator to check that OPAS is obtaining insurance clearances and make 2 appointments with infusion room (9am-1pm each) and with Nuclear Medicine (Todd Hummel, X3550)
9. Obtain informed consent (see attached)

PLAN

Day -1: Start Iodine treatment

Day 0 (Thursday)

Tositumomab 450mg IV (Cancer Center infusion room)

Dosimetric dose I¹³¹ tositumomab (Nuclear Medicine)

Whole body dosimetry (Nuclear Medicine)

Day 2,3 or 4 (Monday, day 4)

Whole body dosimetry (Nuclear Medicine)

Day 6,7 (Wednesday, day 6 or Thursday, day 7):

Whole body dosimetry (Nuclear Medicine)

Day 6-13: RN to check outside Creatinine level 72 hours (Check Monday before a planned Thursday infusion of therapeutic dose) and 24 hours before therapeutic dose is to be given. Values to be reviewed with Heme/Onc attending the same day as obtained, early in the afternoon. If abnormal, contact Nuclear Medicine immediately to review.

Day 7-14: (Thursday)

Tositumomab 450mg IV (Cancer Center infusion room)

Therapeutic I¹³¹ tositumomab dose (Nuclear Medicine)

Thereafter: Arrange for weekly CBC with diff and platelets weekly at least for 10 weeks, with results reviewed carefully, until recovery of counts